Mga Batayang Estadistika
| CIK | 1854270 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Senti Biosciences, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 7, 2025 |
Exhibit 99.1 Senti Bio Reports Second Quarter 2025 Financial Results and Confirms Next Data Milestone for Phase 1 SENTI-202 Study in Acute Myeloid Leukemia (AML) Expected Q4 2025 South San Francisco, Calif., August 7, 2025 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its prop |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40440 Senti Bios |
|
| July 18, 2025 |
Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors Exhibit 99.1 Senti Bio Appoints Entrepreneurial Leader and Investor, Bryan Baum, to Board of Directors SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has a |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 30, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 18, 2025 |
Exhibit 99.1 Senti Bio Granted U.S. FDA Orphan Drug Designation for Use of First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202 to Treat Acute Myeloid Leukemia Ongoing progress in Phase 1 clinical trial of SENTI-202 for the treatment of Acute Myeloid Leukemia (AML) 20,800 newly diagnosed AML patients in the U.S. every year1 with 60% of patients ex |
|
| May 6, 2025 |
Exhibit 99.1 Senti Bio Reports First Quarter 2025 Financial Results and Provides a Corporate Update on Positive SENTI-202 Clinical Development Positive Phase 1 data from lead program, SENTI-202, recently presented at the AACR Annual Meeting: SENTI-202 was generally well tolerated, preliminary RP2D identified; 4 of 7 patients achieved composite Complete Remission (cCR) (3 CR, 1CRh), all 4 cCR patie |
|
| May 6, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2025 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Senti Biosc |
|
| May 6, 2025 |
Consulting Agreement by and between the Company and Yvonne Li, effective as of February 5, 2025. Exhibit 10.1 EXHIBIT A Amended and Restated SOW #2 Under Consulting Agreement Original Effective Date: February 4, 2025 A. Project: Consultant will render such services as Senti may from time to time on an ad-hoc basis request, assist the Company with its ongoing financial and audit matters at the direction of the Company’s CEO and CFO, as applicable. B. Schedule Of Work: This SOW will terminate o |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 28, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (April 28, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| April 28, 2025 |
NASDAQ: SNTI | sentibio.com SENTI-202: Positive Preliminary Results in the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML in Ongoing Phase 1 Trial (SENTI-202-101) April 28, 2025 Conference Call and Webcast Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securit |
|
| April 28, 2025 |
Exhibit 99.2 Senti Bio’s SENTI-202, a First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, Demonstrates Positive Preliminary Clinical Results in the Treatment of Patients with Relapsed/Refractory AML Data presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Dose Finding completed with no dose limiting toxicities and prelimina |
|
| March 31, 2025 |
SENTI BIOSCIENCES, INC. Up to $17,500,000 Common Stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) File No. 333-285985 PROSPECTUS SUPPLEMENT (To Prospectus Dated March 20, 2025) SENTI BIOSCIENCES, INC. Up to $17,500,000 Common Stock We have entered into a sales agreement, dated March 20, 2025, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, relating to the sale of shares of our common stock offered by this prospect |
|
| March 27, 2025 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 March 27, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 File No. 333-285985 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| March 27, 2025 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 March 27, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-3 File No. 333-285983 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| March 24, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 Senti Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Senti Biosciences, Inc. |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS(1) Exhibit 4.3 SENTI BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Senior Debt Securities TABLE OF CONTENTS(1) Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Cert |
|
| March 21, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT Exhibit 1.2 SENTI BIOSCIENCES, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT March 20, 2025 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Senti Biosciences, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance a |
|
| March 21, 2025 |
SENTI BIOSCIENCES, INC. Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS(1) Exhibit 4.4 SENTI BIOSCIENCES, INC. Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 202[●] Subordinated Debt Securities TABLE OF CONTENTS(1) Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’ |
|
| March 21, 2025 |
As filed with the Securities and Exchange Commission on March 20, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 20, 2025 Registration No. |
|
| March 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) SENTI BIOSCIENCES, INC. |
|
| March 20, 2025 |
Senti Bio Announces Fourth Quarter and Full Year 2024 Financial Results and Recent Pipeline and Corporate Highlights – Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened balance sheet with gross proceeds of approximately $47. |
|
| March 20, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| March 20, 2025 |
AMENDMENT NO. 1 TO OPTION AGREEMENT This AMENDMENT NO. 1 TO OPTION AGREEMENT (this “Amendment”) is made and entered into as of December 10, 2024 by and between Senti Biosciences, Inc., a Delaware corporation (the “Company”), and Celadon Partners SPV XVI, a Cayman Islands limited liability company (the “Holder”). Unless otherwise specifically defined herein, all capitalized terms used but not defin |
|
| March 20, 2025 |
Form of Performance Stock Unit Award Agreement. SENTI BIOSCIENCES INC. PSU AWARD GRANT NOTICE (2022 EQUITY INCENTIVE PLAN) Senti Biosciences Inc. (the “Company”) has awarded to you (the “Participant”) the number of performance stock units specified and on the terms set forth below in consideration of your services (the “PSU Award”). Your PSU Award is subject to all of the terms and conditions as set forth herein and in the Company’s 2022 Equity |
|
| March 20, 2025 |
SENTI BIOSCIENCES, INC. AMENDED AND RESTATED INSIDER TRADING POLICY This memorandum sets forth the policy of Senti Biosciences, Inc. and its subsidiaries, if any (collectively, the “Company”), regarding trading in certain securities, including the Company’s securities as described below and the disclosure of information concerning the Company. This Insider Trading Policy (the “Insider Trading Poli |
|
| March 20, 2025 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Annual Report on Form 10-K (the “Annual Report” or “Form 10-K”) as specified in our Second Amended and Restated Certificate of Incorporation (as amended and/or restated from time to |
|
| March 20, 2025 |
AMENDMENT NO. 1 TO FRAMEWORK AGREEMENT This AMENDMENT NO. 1 TO FRAMEWORK AGREEMENT (this “Amendment”) is made and entered into as of December 10, 2024 by and among Senti Biosciences, Inc., a Delaware corporation (“Seller”), Valere Bio, Inc., a Delaware corporation (“TopCo”), and GeneFab, LLC, a Delaware limited liability company (“Purchaser”). Unless otherwise specifically defined herein, all capi |
|
| March 20, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2025 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 20, 2025 |
AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT THIS AMENDED AND RESTATED DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is made as of December 10, 2024 (the “Effective Date”) by and between GeneFab, LLC, a Delaware limited company (“Provider”), with offices at 1430 Harbor Bay Parkway, Alameda, CA 94502, and Senti Biosciences, Inc. |
|
| March 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 10, 2025 (March 6, 2025) Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) |
|
| March 10, 2025 |
SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Exhibit 10.3 SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) of Senti Biosciences Inc. (the “Company”) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Compa |
|
| March 10, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 10.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| March 7, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 10.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 7, 2025 (March 6, 2025) Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) ( |
|
| March 7, 2025 |
2022 Inducement Plan and forms of award agreements thereunder Exhibit 99.3 SENTI BIOSCIENCES, INC. Amended and Restated 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: March 7, 2025 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 5 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS |
|
| March 7, 2025 |
As filed with the Securities and Exchange Commission on March 7, 2025 As filed with the Securities and Exchange Commission on March 7, 2025 Registration No. |
|
| March 7, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| March 7, 2025 |
SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN Exhibit 99.1 SENTI BIOSCIENCES INC. AMENDED AND RESTATED 2022 EQUITY INCENTIVE PLAN 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and any Affiliate and to provide a means by which such persons may be given |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (February 23, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commis |
|
| February 25, 2025 |
Senti Bio Strengthens Leadership Team with Strategic Hires – Jay Cross, proven financial leader, appointed as CFO to drive strategic growth – – Faraz Siddiqui, expert in manufacturing operations, joins as SVP Technical Operations – SOUTH SAN FRANCISCO, Calif. |
|
| February 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): (January 31, 2025) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commiss |
|
| January 27, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as per |
|
| January 15, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permi |
|
| January 6, 2025 |
Exhibit 99.1 Senti Bio Announces Additional $11.5 Million of Financing – Approximately $10 million additional investment in private placement equity financing – – $1.5 million from CIRM grant first announced in June 2024 – – Cash runway guidance extended into 2026 – SOUTH SAN FRANCISCO, Calif., January 6, 2025 – Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stag |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 16, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| December 16, 2024 |
Senti Bio Announces First Patient Dosed in Clinical Trial of SN301A in Hepatocellular Carcinoma in Collaboration with Celest Therapeutics – Dose-finding clinical trial in China designed to evaluate safety and preliminary anti-tumor activity of SN301A (SENTI-301A manufactured in China) in hepatocellular carcinoma (“HCC”) – SOUTH SAN FRANCISCO, Calif. |
|
| December 4, 2024 |
SC 13D/A 1 nea1518913.htm NEW ENTERPRISE ASSOCIATES 15, L.P. / SENTI BIOSCIENCES, INC. - SCHEDULE 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Senti Biosciences, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 81726A209 (CUSIP Number) Stephanie Brecher |
|
| December 3, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 3, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 3, 2024 |
SENTI-202 Initial Clinical Data December 2024 Exhibit 99.1 SENTI-202 Initial Clinical Data December 2024 Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements of Senti Biosciences, Inc. ("we," "us," "our”) within the meaning of the Private Securities Litigation Reform Act of 1995. Statements we make in this presentation may include statements which are not historical facts and are considered forward-loo |
|
| December 2, 2024 |
Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REG |
|
| December 2, 2024 |
Exhibit 10.4 Execution Version Designation Agreement December 2, 2024 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 New Enterprises Associates 15, L.P. 1954 Greenspring Drive, Suite 600, Timonium, MD 20193 Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to that certain Securities Purchase Agreement, dated as of the date hereof, |
|
| December 2, 2024 |
Exhibit 10.3 Execution Version Designation Agreement December 2, 2024 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Celadon Partners SPV 24 PO Box 500 71 Fort Street Grand Cayman, KY1-1106 Cayman Islands Ladies and Gentlemen: Reference is hereby made in this agreement (“Agreement”) to that certain Securities Purchase Agreement, dated as of the date hereof, by |
|
| December 2, 2024 |
Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of December 2, 2024, is entered into by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). C |
|
| December 2, 2024 |
Exhibit 10.1 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of December 2, 2024, by and among Senti Biosciences, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are execut |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 2, 2024 Senti Biosciences, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40440 86-2437900 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| December 2, 2024 |
Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing Exhibit 99.2 Senti Biosciences, Inc. Announces Oversubscribed $37.6 Million Private Placement Equity Financing SOUTH SAN FRANCISCO, Calif., December 2, 2024 – Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, has entered into a securities purch |
|
| December 2, 2024 |
Exhibit 99.1 Senti Bio Announces Positive Initial Clinical Data in Phase 1 Clinical Trial of SENTI-202, a Logic Gated, Selective CD33/FLT3-Targeting CAR-NK Cell Therapy for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML – 2 of 3 patients achieved MRD negative CR in the first dose level evaluated in the trial with a generally well-tolerated preliminary safety profile – |
|
| December 2, 2024 |
Senti Bio Appoints Fran Schulz to Board of Directors Exhibit 99.1 Senti Bio Appoints Fran Schulz to Board of Directors – Biotechnology industry executive with a proven track record of advising management teams on corporate and financial strategy for more than 30 years – SOUTH SAN FRANCISCO, Calif., December 2, 2024 - Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generati |
|
| December 2, 2024 |
Exhibit 3.1 SENTI BIOSCIENCES, INC. CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES A CONVERTIBLE PREFERRED STOCK PURSUANT TO SECTION 151 OF THE DELAWARE GENERAL CORPORATION LAW SENTI BIOSCIENCES, INC., a Delaware corporation (the “Corporation”), in accordance with the provisions of Section 103 of the Delaware General Corporation Law (the “DGCL”) does hereby certify tha |
|
| November 14, 2024 |
Therapeutics, Inc., dated as of September 23, 2024. Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. STORAGE LICENSE AGREEMENT THIS STORAGE LICENSE AGREEMENT (the “License”) entered into as of September 23, |
|
| November 14, 2024 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE Two Corporate Drive, First Floor South San Francisco, CA This Sublease (“Sublease”), dated Septe |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2024 |
Senti Bio Announces Third Quarter 2024 Results and Recent Pipeline and Corporate Highlights – Enrollment continues in Phase 1 clinical trial of SENTI-202 for the treatment of relapsed/refractory hematologic malignancies including AML; initial clinical data expected in Q4 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| October 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 (October 22, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorp |
|
| September 27, 2024 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2024 (September 23, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of in |
|
| August 13, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Sen |
|
| August 13, 2024 |
Consulting Agreement by and between the Company and Yvonne Li, Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SENTI BIOSCIENCES, INC. CONSULTING AGREEMENT Effective Date: May 3, 2024 This Consulting Agreement (the “ |
|
| August 13, 2024 |
Senti Bio Announces Second Quarter 2024 Results and Reviews Recent Corporate and Pipeline Highlights – Dose Finding Ongoing in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed/Refractory Hematologic Malignancies Including AML – – Commencement of $8 Million Grant Award from CIRM for the Clinical Development of SENTI-202 – SOUTH SAN FRANCISCO, Calif. |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 13, 2024 |
Sublease Agreement by and between the Company and GeneFab Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 7th day of May |
|
| August 13, 2024 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SENTI BIOSCIENCES, INC. AMENDED AND RESTATED CONSULTING AGREEMENT Effective Date: May 4, 2024 This Amende |
|
| July 17, 2024 |
Exhibit 4.1 SPECIMEN COMMON STOCK CERTIFICATE NUMBER C–[ ] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 81726A 209 SENTI BIOSCIENCES, INC. COMMON STOCK THIS CERTIFIES THAT [ ] is the owner of fully paid and non-assessable shares of common stock, par value US $0.0001 per share, of Senti Biosciences, Inc., a Delaware corporation (the “Company”), subject to the Company’s certificate of incorporat |
|
| July 17, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENTI BIOSCIENCES, INC. Senti Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the Board of Directors of the Corporation has duly adopted resolutions |
|
| July 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| July 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| July 16, 2024 |
Exhibit 10.1 AMENDED AND RESTATED ChEF PURCHASE AGREEMENT This AMENDED AND RESTATED ChEF PURCHASE AGREEMENT is made and entered into as of July 16, 2024 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Senti Biosciences, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, on August 31, 2022 |
|
| July 12, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SENTI BIOSCIENCES, INC. Senti Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. That the Board of Directors of the Corporation has duly adopted resolutions |
|
| July 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 12, 2024 (July 10, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporatio |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2024 (May 14, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) |
|
| May 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: x Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 9, 2024 |
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights – First patient dosing of SENTI-202, a first-in-class logic-gated treatment for acute myeloid leukemia (“AML”), on track for the second quarter of 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| May 9, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Se |
|
| May 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 (April 26, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A Amendment No.1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-4044 |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2024 (April 23, 2024) SENTI BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporat |
|
| March 21, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| March 21, 2024 |
iences, Inc., and Celest Therapeutics (Shanghai) Co. Exhibit 10.41 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. COLLABORATION AND OPTION AGREEMENT This Collaboration and Option Agreement (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of November 6, 2023 (t |
|
| March 21, 2024 |
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights – IND for SENTI-202, a potential first-in-class logic-gated treatment for AML, cleared by the U. |
|
| March 21, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 21, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2024 |
Senti Biosciences, Inc. Compensation Recovery Policy Exhibit 97 SENTI BIOSCIENCES, INC. COMPENSATION RECOVERY POLICY Senti Biosciences, Inc., a Delaware corporation (the “Company”), has adopted a Compensation Recovery Policy (this “Policy”) as described below. 1. Overview The Policy sets forth the circumstances and procedures under which the Company shall recover Erroneously Awarded Compensation from Covered Persons (as defined below) in accordance |
|
| February 6, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| January 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| January 10, 2024 |
As filed with the Securities and Exchange Commission on January 10, 2024 As filed with the Securities and Exchange Commission on January 10, 2024 Registration No. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2024 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| January 5, 2024 |
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program – Strategic resource allocation to focus investment on clinical development of SENTI-202 and SENTI-301A partnership in China; interim data from Phase 1 clinical trial of SENTI-202 expected in 2H 2024 – – Anticipated cost savings, which includes an approximately 37% reduction in workforce, expected to extend cash runway into 1Q 2025 – SOUTH SAN FRANCISCO, Calif. |
|
| December 22, 2023 |
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia – First patient in Phase 1 clinical trial expected to be treated in Q2 2024 – – Initial clinical efficacy data expected by year-end 2024 and durability data expected in 2025 – – SENTI-202 is a potential first-in-class off-the-shelf CAR-NK cell therapy using Logic Gated Gene Circuits to selectively target cancer cells while sparing healthy bone marrow cells – SOUTH SAN FRANCISCO, Calif. |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| November 14, 2023 |
Sublease Agreement by and between Senti Biosciences, Inc. and GeneFab, LLC dated August 7, 2023. Exhibit 10.4 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SUBLEASE AGREEMENT THIS SUBLEASE AGREEMENT (this “Sublease”) is made and entered into this 7th day of Aug |
|
| November 14, 2023 |
Exhibit 10.2 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. SELLER ECONOMIC SHARE AGREEMENT This Seller Economic Share Agreement (this “Agreement”) is entered into a |
|
| November 14, 2023 |
Exhibit 10.1 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. [***] FRAMEWORK AGREEMENT by and among SENTI BIOSCIENCES, INC., VALERE BIO, INC. and GENEFAB, LLC DATED A |
|
| November 14, 2023 |
Exhibit 10.3 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT THIS DEVELOPMENT AND MANUFACTURING SERVICES AGREEMENT (t |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 13, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 PROSPECTUS SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (“Chardan” or the “Selling Securityholder”) of up to 8,727,049 shares of our common stock, par value $0.0001 per share (“Senti Common Shares”) that have been or |
|
| November 13, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 PROSPECTUS SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus relates to the issuance by us of up to 2,000,000 shares of our common stock, par value $0.0001 per share (“Senti Common Shares”) that may be issued as Contingency Consideration from time to time upon achievement of certain stock price thresholds (the “Ea |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| November 13, 2023 |
Senti Bio Announces Third Quarter 2023 Results and Pipeline Updates – IND for SENTI-202, a potential first-in-class logic-gated treatment for cancer, on track for clearance in Q4 2023 – – Established new strategic collaboration with Celest Therapeutics for clinical development of SENTI-301A to treat liver cancer in China – – Cash and receivables from GeneFab transaction expected to fund operations into Q4 2024 – SOUTH SAN FRANCISCO, Calif. |
|
| November 6, 2023 |
Senti Bio Announces New Strategic Collaboration with Celest Therapeutics for Clinical Development of SENTI-301A in China – Celest to lead clinical development with technical support from Senti Bio – – First patient expected to be enrolled in China in 1H 2024 – – Senti Bio eligible to receive up to $156 million in milestones and royalties – SOUTH SAN FRANCISCO, Calif. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
As filed with the Securities and Exchange Commission on November 1, 2023 As filed with the Securities and Exchange Commission on November 1, 2023 Registration No. |
|
| November 1, 2023 |
Option Agreement by and between Senti Biosciences, Inc. and GeneFab, LLC, dated August 7, 2023 Exhibit 10.8 Execution Version Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, CA 94080 Au |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 9 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| August 11, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Sen |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 12 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 12 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 11, 2023 |
Senti Bio Announces Second Quarter 2023 Results and Pipeline Updates – GeneFab transaction provides access to clinical manufacturing and extends cash runway into Q4 2024 – – IND for SENTI-202, potentially the first Logic Gated CAR-NK treatment for AML, on track for 2H 2023 – – Cash, cash equivalents, and short-term investments of $59. |
|
| August 11, 2023 |
Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 11 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 11 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 11, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 10 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms p |
|
| August 10, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 10 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 10 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Re |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 10, 2023 |
Senti Bio Announces Closing of Transaction Leveraging its CMC Capabilities into a Cell and Gene Therapy Manufacturing Innovation Business Backed by Celadon Partners – Celadon Partners to acquire Senti’s manufacturing facility and CMC capabilities to establish GeneFab, an independent manufacturing business for cell and gene therapies – – Transaction anticipated to extend Senti Bio’s cash runway into Q4 2024 – – Partnership with GeneFab will support manufacturing of Senti’s oncology programs, including SENTI-202, which remains on track for IND in 2H 2023 – – Dr. |
|
| August 10, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 8 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| June 23, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 9 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 9 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 23, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 7 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| May 9, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 8 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 8 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| May 9, 2023 |
Employee Offer Letter by and between Kanya Rajangam and Senti Biosciences, Inc., dated May 10, 2022. Exhibit 10.1 May 10, 2022 Kanya Rajangam VIA EMAIL Re: Offer of Employment Dear Kanya: Senti Biosciences, Inc. (the “Company”) is pleased to offer you employment as the Company’s Chief Medical & Development Officer (“CMDO”) on the terms and conditions set forth in this letter agreement (the “Agreement”). 1. Commencement of Employment. Your employment with the Company will commence on July 5, 2022 |
|
| May 9, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Se |
|
| May 9, 2023 |
Senti Bio Announces First Quarter 2023 Results and Pipeline Updates – New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform can work in T cells, AAVs, and iPSCs – – Cash, cash equivalents, and short-term investments of $76. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission Fil |
|
| May 9, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock 424B3 1 a20230509424b3333-267390xs.htm 424B3 Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 6 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from ti |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)( |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| April 28, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 5 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| April 28, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 7 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 7 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| March 23, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 4 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 4 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| March 23, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 6 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 6 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| March 22, 2023 |
Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights - SENTI-202 on track to submit an Investigational New Drug (IND) application in second half of 2023 for treatment of CD33 and/or FLT3 expressing hematologic malignancies including AML and MDS - - Preclinical data from multiple Gene Circuit enhanced CAR NK programs to be presented at American Association for Cancer Research (AACR) Annual Meeting in April 2023 - - Cash, cash equivalents, and short-term investments of $98. |
|
| March 22, 2023 |
Exhibit 10.13 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT SENTI BIOSCIENCES, INC. TREATS AS PRIVATE OR CONFIDENTIAL. RESEARCH AND DEVELOPMENT AND LABORATORY LEASE AGREEMENT BETWEEN 1430 HARBOR BAY PKWY LLC AS LANDLORD AND SENTI BIOSCIENCES, INC. AS TENANT DATED JUNE 3 , 2021 1 TABLE OF |
|
| March 22, 2023 |
Exhibit 10.32 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. AMENDMENT NO. 1 TO THE RESEARCH COLLABORATION AND LICENSE AGREEMENT BETWEEN SPARK THERAPEUTICS, INC. AND |
|
| March 22, 2023 |
Side Letter between BlueRock Therapeutics, LP and Senti Biosciences, Inc., dated February 3, 2023. Exhibit 10.33 Certain identified information has been excluded from this exhibit because it is both not material and is the type that the registrant treats as private or confidential. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”. February 3, 2023 Senti Biosciences, Inc. 2 Corporate Drive South San Francisco, CA 94080 Attn: Chief Exe |
|
| March 22, 2023 |
Scientific Advisory Board Agreement between Senti Biosciences, Inc. and James Collins. Exhibit 10.34 SENTI BIOSCIENCES, INC. SCIENTIFIC ADVISORY BOARD AGREEMENT THIS SCIENTIFIC ADVISORY BOARD AGREEMENT (the “Agreement”) is made and entered into as of May 14, 2021 (the “Effective Date”), by and between SENTI BIOSCIENCES, INC., a Delaware corporation (the “Company”), and DR. JAMES COLLINS an individual with an email address at [email protected] (the “Advisor”). The Company and the Advisor |
|
| March 22, 2023 |
Exhibit 4.3 DESCRIPTION OF SECURITIES The following description summarizes certain important terms of the capital stock of Senti Biosciences, Inc. (the “Company,” “Senti,” “we,” “us,” and “our”) as of the date of this Annual Report on Form 10-K (the “Annual Report” or “Form 10-K”) as specified in our Second Amended and Restated Certification of Incorporation (the “Charter”) and our Amended and Res |
|
| March 22, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| March 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 22, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| February 16, 2023 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| February 16, 2023 |
As filed with the Securities and Exchange Commission on February 15, 2023 As filed with the Securities and Exchange Commission on February 15, 2023 Registration No. |
|
| February 14, 2023 |
SNTI / Senti Biosciences Inc. / Sculptor Capital LP - SC 13G/A Passive Investment SC 13G/A 1 d405260dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* SENTI BIOSCIENCES INC (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Chec |
|
| February 13, 2023 |
SNTI / Senti Biosciences Inc. / BAYER HEALTHCARE LLC - SC 13G Passive Investment SC 13G 1 tm236386d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (Amendment No. )* Under the Securities Exchange Act of 1934 Senti Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 10, 2023 |
SNTI / Senti Biosciences Inc. / Woodline Partners LP - SENTI BIOSCIENCES, INC. Passive Investment SC 13G/A 1 p23-0152sc13ga.htm SENTI BIOSCIENCES, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Senti Biosciences, Inc. (f/k/a Dynamics Special Purpose Corp.) (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 81726A100 (CUSIP Number) December 31, 2022 (Date of event w |
|
| February 8, 2023 |
SNTI / Senti Biosciences Inc. / Lonsdale Joe - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Senti Biosciences, Inc. (Name of Issuer) Class A Common Stock, $0.0001 par value per share (Title of Class of Securities) 81726A100 (CUSIP Number) June 8, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to des |
|
| February 8, 2023 |
EX-99.1 2 d443944dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| January 27, 2023 |
™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Engineering the Future of Cell and Gene Therapies 1 January 2023 JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. |
|
| January 27, 2023 |
EX-99.1 2 a20230127ex991pressrelease.htm PRESS RELEASE Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance – R&D focus is on lead oncology candidate SENTI-202 for the treatment of AML and other CD33 and/or FLT3 expressing hematologic malignancies, and SENTI-401 to target colorectal cancer and other CEA-positive solid tumors – – SENTI-202 |
|
| January 27, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| January 27, 2023 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 5 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms part of our Regi |
|
| January 27, 2023 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 3 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 3 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the “Prospectus”) which forms par |
|
| January 9, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
EX-99.1 2 corporatepresentation1-.htm PRESENTATION ™ JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Corporate Presentation 1 January 2023 JA N U A R Y 2 0 2 3 | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. Statements we make in this presentation may include statements which are not historical facts and are considered |
|
| December 12, 2022 |
Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event – ASH poster presentation summarizes preclinical data from SENTI-202, an off-the-shelf CAR-NK cell therapy candidate engineered with a logic-gated gene circuit and multi-armed with crIL-15, that is advancing toward clinical development for hematologic malignancies – – SENTI-202 is on track for IND filing in 2H 2023 – – SENTI-202 aims to more precisely target tumor cells in CD33 and/or FLT3 expressing tumors such as acute myeloid leukemia and myelodysplastic syndrome, while sparing healthy cells – – Senti Bio Investor Event to include an AML expert; in-person and webcast at 12:30 p. |
|
| December 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 11, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| December 12, 2022 |
corporatepresentation12 D E C E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S Corporate Presentation December 2022 ™ D E C E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S 2 Disclaimer Forward Looking Statements This presentation contains forward-looking statements. |
|
| December 12, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 4 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 4 (this ?Prospectus Supplement?) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms part of our Regi |
|
| December 12, 2022 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 2 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 2 (this ?Prospectus Supplement?) amends and supplements the prospectus dated September 29, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms par |
|
| December 12, 2022 |
investoreventpresentatio ™ D E C E M B E R 2 0 2 2 IN V E ST O R E V E N T | SE N T I B IO SC IE N C E S Investor Event 1 December 2022 D E C E M B E R 2 0 2 2 IN V E ST O R E V E N T | SE N T I B IO SC IE N C E S Disclaimer 2 Forward Looking Statements This presentation contains forward-looking statements. |
|
| November 14, 2022 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock 424B3 1 senti093022424b3333-267390.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 Prospectus Supplement No. 1 (To Prospectus dated September 29, 2022) SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated September 29, 2022 (as supplemented |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Philip Lee. EX-10.4 5 a9302210qex104.htm SEVERANCE AGREEMENT BETWEEN THE COMPANY AND PHILIP LEE Exhibit 10.4 July 13, 2022 Philip Lee, Ph.D., Co-founder and CTO VIA EMAIL Re: Severance & Change in Control Agreement Dear Philip: Effective as of the date first written above, this letter agreement (the “Agreement”) sets forth your rights to receive severance payments or benefits upon an involuntary termination o |
|
| November 10, 2022 |
N O V E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S Corporate Presentation November 2022 ? N O V E M B E R 2 0 2 2 | SE N T I B IO SC IE N C E S 2 Disclaimer Forward Looking Statements This presentation contains forward-looking statements. |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Tim Lu. Exhibit 10.5 July 13, 2022 Tim Lu, Ph.D., M.D., Co-founder, President and CEO VIA EMAIL Re: Severance & Change in Control Agreement Dear Tim: Effective as of the date first written above, this letter agreement (the ?Agreement?) sets forth your rights to receive severance payments or benefits upon an involuntary termination of your employment with Senti Biosciences, Inc. (the ?Company?) or its subs |
|
| November 10, 2022 |
Severance and Change in Control Agreement between the Company and Deborah Knobelman. EX-10.3 4 a9302210qex103.htm SEVERANCE AGREEMENT BETWEEN THE COMPANY AND DEBORAH KNOBELMAN Exhibit 10.3 July 13, 2022 Deborah Knobelman, Ph.D., CFO VIA EMAIL Re: Severance & Change in Control Agreement Dear Deb: Effective as of the date first written above, this letter agreement (the “Agreement”) sets forth your rights to receive severance payments or benefits upon an involuntary termination of yo |
|
| November 10, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-4044 |
|
| November 10, 2022 |
Senti Biosciences, Inc. 2022 Inducement Plan and form of award agreements thereunder. EX-10.6 7 a9302210qex106.htm 2022 INDUCEMENT PLAN Exhibit 10.6 Senti Biosciences, Inc. 2022 Inducement Plan Adopted by the Board of Directors: August 5, 2022 Table of Contents 1 General 1 2 Shares Subject to the Plan 1 3 Eligibility and Limitations 2 4 Options and Stock Appreciation Rights 2 5 Awards Other Than Options and Stock Appreciation Rights 5 6 Adjustments upon Changes in Common Stock; Oth |
|
| November 10, 2022 |
Senti Bio Reports Third Quarter Financial Results and Pipeline Updates - SENTI-202 on track for IND filing in 2023; clinical plans for SENTI-202 expand beyond AML to CD33 and/or FLT3 expressing hematologic malignancies including MDS - - Selected development candidate for program to treat GPC3-expressing solid tumors including HCC, SENTI-301A; expected IND filing in 2023 - - Preclinical data from two solid tumor CAR-NK programs highlighted at SITC - - Cash position of $114. |
|
| November 10, 2022 |
Consulting Agreement between Senti Biosciences, Inc. and David Epstein. Exhibit 10.2 SENTI BIOSCIENCES, INC. CONSULTING AGREEMENT Effective Date: July 1, 2022 This Consulting Agreement (the ?Agreement?) is made as of the Effective Date set forth above by and between Senti Biosciences, Inc., a Delaware corporation (?Client?) and the Advisor named on the signature page hereto (?Advisor?). 1.Engagement of Services. Client may issue Project Assignments to Advisor in the f |
|
| November 10, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 3 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 3 (this ?Prospectus Supplement?) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which form |
|
| November 10, 2022 |
Non-Employee Director Compensation Policy. Exhibit 10.1 SENTI BIOSCIENCES INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY The purpose of this Non-Employee Director Compensation Policy (the ?Policy?) of Senti Biosciences Inc. (the ?Company?) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiarie |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commissi |
|
| October 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commis |
|
| October 3, 2022 |
EX-99.1 2 corporatepresentation9-.htm PRESENTATION O C T O B E R 2 0 2 2 | SE N T I B IO SC IE N C E S Corporate Presentation 1 October 2022 ™ O C T O B E R 2 0 2 2 | SE N T I B IO SC IE N C E S 2 Disclaimer Forward Looking Statements This presentation contains forward-looking statements. Statements we make in this presentation may include statements which are not historical facts and are consider |
|
| September 30, 2022 |
SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-267390 PROSPECTUS SENTI BIOSCIENCES, INC. Up to 8,727,049 Shares of Common Stock This prospectus relates to the potential offer and sale from time to time by Chardan Capital Markets LLC (?Chardan? or the ?Selling Securityholder?) of up to 8,727,049 shares of our common stock, par value $0.0001 per share (?Senti Common Shares?) |
|
| September 27, 2022 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 September 27, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance ? Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-1 File No. 333-267390 Request for Acceleration Ladies and Gentlemen: Pursuant to R |
|
| September 12, 2022 |
Senti Biosciences, Inc. 2022 Inducement Plan and forms of award agreements thereunder Exhibit 10.24 SENTI BIOSCIENCES, INC. 2022 INDUCEMENT PLAN ADOPTED BY THE BOARD OF DIRECTORS: AUGUST 5, 2022 TABLE OF CONTENTS Page 1. GENERAL 1 2. SHARES SUBJECT TO THE PLAN 1 3. ELIGIBILITY AND LIMITATIONS 2 4. OPTIONS AND STOCK APPRECIATION RIGHTS 2 5. AWARDS OTHER THAN OPTIONS AND STOCK APPRECIATION RIGHTS 5 6. ADJUSTMENTS UPON CHANGES IN COMMON STOCK; OTHER CORPORATE EVENTS 7 7. ADMINISTRATIO |
|
| September 12, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Senti Biosciences, Inc. |
|
| September 12, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on September 12, 2022 Registration No. |
|
| September 1, 2022 |
EX-10.1 2 a202208318kex101.htm EX-10.1 Exhibit 10.1 ChEF PURCHASE AGREEMENT This ChEF PURCHASE AGREEMENT is made and entered into as of August 31, 2022 (together with Annex I, this “Agreement”), by and between Chardan Capital Markets LLC, a New York limited liability company (the “Investor”), and Senti Biosciences, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, the parties desire |
|
| September 1, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of August 31, 2022, is by and between Chardan Capital Markets LLC, a New York limited liability company (the ?Investor?), and Senti Biosciences, Inc., a Delaware corporation (the ?Company?). RECITALS The Company and the Investor have entered into that certain Common Stock Purchase Agreement, |
|
| September 1, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 2 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 2 (this ?Prospectus Supplement?) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from time to time, the ?Prospectus?) which forms part of our Regi |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commissio |
|
| August 18, 2022 |
Power of Attorney (included on signature page of this registration statement). Exhibit 24.1 POWER OF ATTORNEY AND SIGNATURES KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below hereby constitutes and appoints each of Timothy Lu and Deborah Knobelman as such person?s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person?s name, place and stead, in any and all capacities, |
|
| August 18, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) Senti Biosciences, Inc. |
|
| August 18, 2022 |
S-8 1 a081622s-8doc.htm S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 86-2437900 (IRS Employer Identification No.) Senti Biosciences, Inc. 2022 Equity Incentive Plan Sent |
|
| August 15, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period from to Commission File Number 001-40440 Sen |
|
| August 15, 2022 |
Senti Biosciences, Inc. 2022 Equity Incentive Plan and forms of award agreements thereunder. Exhibit 10.3 SENTI BIOSCIENCES INC. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: June 8, 2022 APPROVED BY THE STOCKHOLDERS: June 7, 2022 1. GENERAL. (a) Plan Purpose. The Company, by means of the Plan, seeks to secure and retain the services of Employees, Directors and Consultants, to provide incentives for such persons to exert maximum efforts for the success of the Company and a |
|
| August 15, 2022 |
Senti Biosciences, Inc. 2022 Employee Stock Purchase Plan. Exhibit 10.4 Senti Biosciences Inc. 2022 Employee Stock Purchase Plan ADOPTED BY THE BOARD OF DIRECTORS: June 8, 2022 APPROVED BY THE STOCKHOLDERS: June 7, 2022 1.GENERAL; PURPOSE. a.The Plan provides a means by which Eligible Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a |
|
| August 15, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| August 15, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock 424B3 1 senti06302210qfor424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 Prospectus Supplement No. 1 (To Prospectus dated August 8, 2022) SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus supplement no. 1 (this “Prospectus Supplement”) amends and supplements the prospectus dated August 8, 2022 (as supplemented or amended from t |
|
| August 15, 2022 |
Senti Bio Reports Second Quarter Financial Results and Business Updates - Lead development candidate selected from SENTI-202 program; on track for IND filing in 2023 - - Expect to present CAR-NK cell therapy program data at multiple scientific conferences in 2022 - - Cash position of $139. |
|
| August 9, 2022 |
SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock 424B3 1 d354156d424b3.htm 424B3 Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-265873 PROSPECTUS SENTI BIOSCIENCES, INC. 35,444,908 Shares of Common Stock This prospectus relates to the issuance by us of up to 2,000,000 shares of our common stock, par value $0.0001 per share (“Senti Common Shares”) that may be issued as Contingency Consideration from time to time upon achi |
|
| August 4, 2022 |
Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 August 4, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance – Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Senti Biosciences, Inc. Registration Statement on Form S-1 File No. 333-265873 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule |
|
| July 29, 2022 |
As filed with the Securities and Exchange Commission on July 29, 2022 Table of Contents As filed with the Securities and Exchange Commission on July 29, 2022 Registration No. |
|
| July 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| July 29, 2022 |
Goodwin Procter LLP Three Embarcadero Center, 28th Floor San Francisco, CA 94111 goodwinlaw. |
|
| July 19, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commission |
|
| July 15, 2022 |
Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Senti Biosciences, Inc. (Name of Issuer) Common Stock, $.0001 par value (Title of Class of Securities) 81726A100 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842- |
|
| June 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Senti Biosciences, Inc. |
|
| June 28, 2022 |
Table of Contents As filed with the Securities and Exchange Commission on June 2 8 , 2022 Registration No. |
|
| June 15, 2022 |
Investor Rights and Lock-up Agreement. Exhibit 10.4 INVESTOR RIGHTS AND LOCK-UP AGREEMENT THIS INVESTOR RIGHTS AND LOCK-UP AGREEMENT (this ?Agreement?) is entered into as of June 8, 2022, by and among Dynamics Special Purpose Corp., a Delaware corporation, (the ?Company?) and the parties listed as Investors on Schedule I hereto (each, including any person or entity who hereinafter becomes a party to this Agreement pursuant to Section 8 |
|
| June 15, 2022 |
Exhibit 99.1 SENTI BIOSCIENCES, INC. INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Page Condensed Consolidated Financial Statements: Condensed Consolidated Balance Sheets F-2 Condensed Consolidated Statements of Operations and Comprehensive Loss F-3 Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders? Deficit F-4 Condensed Consolidated Statements of |
|
| June 15, 2022 |
SENTI MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS Exhibit 99.3 SENTI MANAGEMENT?S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS On June 6, 2022, Senti Biosciences, Inc. changed its name to Senti Sub I, Inc. For purposes of this section, all references to ?we,? ?us,? ?our,? ?Senti? or the ?Company? refer to Senti Sub I, Inc. and its subsidiary. You should read the following discussion and analysis of our financial condit |
|
| June 15, 2022 |
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION The following unaudited pro forma condensed combined financial statements present the combination of the financial information of DYNS and Senti after giving effect to the Business Combination. On the Closing Date of the Business Combination, the following transactions (collectively, the ?Transactions?) were completed, and t |
|
| June 15, 2022 |
Second Amended and Restated Certificate of Incorporation of Senti Biosciences, Inc. Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF DYNAMICS SPECIAL PURPOSE CORP. Dynamics Special Purpose Corp., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: 1. The name of the Corporation is Dynamics Special Purpose Corp. The Corporation was incorporated under the name ?Dynamics Special Purpose |
|
| June 15, 2022 |
Exhibit 21.1 LIST OF SUBSIDIARIES OF THE REGISTRANT The following are the subsidiaries of Senti Biosciences, Inc, omitting certain subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary: Name State or Other Jurisdiction of Organization Senti Sub I, Inc. DE |
|
| June 15, 2022 |
Amended and Restated Bylaws of Senti Biosciences, Inc. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SENTI BIOSCIENCES, INC. (the ?Corporation?) ARTICLE I Stockholders SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an ?Annual Meeting?) shall be held at the hour, date and place within or without the United States which is fixed by the Corporation?s Board of Directors (the ?Board of Dire |
|
| June 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 15, 2022 |
Specimen Common Stock Certificate Exhibit 4.1 SPECIMEN COMMON STOCK CERTIFICATE NUMBER C?[ ] SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP [ ] SENTI BIOSCIENCES, INC. COMMON STOCK THIS CERTIFIES THAT [ ] is the owner of fully paid and non-assessable shares of common stock, par value US $0.0001 per share, of Senti Biosciences, Inc., a Delaware corporation (the ?Company?), subject to the Company?s certificate of incorporation, as |
|
| June 15, 2022 |
Letter from Marcum LLC to the SEC Exhibit 16.1 June 14, 2022 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Senti Biosciences, Inc. (formerly Dynamics Special Purpose Corp.) under Item 4.01 of its Form 8-K filed June 14, 2022. We agree with the statements concerning our Firm under Item 4.01 of such Form 8-K; we are not in a position to agree or disagree |
|
| June 9, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2022 SENTI BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 333-262707 86-2437900 (State or other jurisdiction of incorporation) (Commission F |
|
| June 9, 2022 |
EX-99.1 2 d355091dex991.htm EX-99.1 Exhibit 99.1 Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits - Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti Bio will be listed o |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| June 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2022 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| May 25, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| May 25, 2022 |
EX-99.1 2 d358398dex991.htm EX-99.1 Exhibit 99.1 Senti Bio Names Dr. Kanya Rajangam to Newly Created Position of Chief Medical and Development Officer - Cell therapy and oncology drug development expert aims to lead Senti Bio’s novel off-the-shelf CAR-NK cell oncology programs into and through clinical development - SOUTH SAN FRANCISCO, Calif., May 25, 2022 — Senti Biosciences, Inc. (Senti Bio), a |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of incorporation |
|
| May 24, 2022 |
Exhibit 99.1 Senti Bio Secures Additional Financing from Leaps by Bayer and Provides Update on Proposed Business Combination with Dynamics Special Purpose Corp. (DYNS) - Leaps by Bayer led Series B investment in Senti Bio in 2021; Additional Convertible Note financing expands committed capital to PIPE investment associated with previously announced Business Combination Agreement with DYNS - - DYNS |
|
| May 24, 2022 |
Exhibit 2.1 Execution version AMENDMENT NO. 2 TO BUSINESS COMBINATION AGREEMENT This AMENDMENT NO. 2 TO BUSINESS COMBINATION AGREEMENT (this ?Amendment?), dated as of May 19, 2022, is made by and among Dynamics Special Purpose Corp., a Delaware corporation (?DYNS?), Explore Merger Sub, Inc., a Delaware corporation (?Merger Sub?), and Senti Biosciences, Inc., a Delaware corporation (the ?Company?). |
|
| May 24, 2022 |
Exhibit 10.2 Execution version THIS PROMISSORY NOTE AND THE SECURITIES ISSUABLE UPON CONVERSION HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY STATE SECURITIES LAWS. THESE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO DISTRIBUTION OR RESALE, AND MAY NOT BE MORTGAGED, PLEDGED, HYPOTHECATED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGI |
|
| May 24, 2022 |
Exhibit 10.1 Execution version SUBSCRIPTION AGREEMENT Senti Biosciences, Inc. 2 Corporate Drive, First Floor South San Francisco, California 94080 This Subscription Agreement (this ?Subscription Agreement?) is being entered into in connection with the proposed business combination (the ?Transaction?) between Dynamics Special Purpose Corp., a Delaware corporation (?Dynamics?), and Senti Biosciences |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 (May 19, 2022) DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 (May 19, 2022) DYNAMICS SPECIAL PURPOSE CORP. (Exact name of registrant as specified in its charter) Delaware 001-40440 86-2437900 (State or other jurisdiction of |
|
| May 16, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-40440 D |
|
| May 13, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi |
|
| May 13, 2022 |
424B3 1 d189920d424b3.htm 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-262707 PROXY STATEMENT FOR SPECIAL MEETING OF DYNAMICS SPECIAL PURPOSE CORP. PROSPECTUS FOR 26,000,000 SHARES OF CLASS A COMMON STOCK All of the members of the board of directors of Dynamics Special Purpose Corp., a Delaware corporation (“DYNS”), voting on the transaction approved the Business C |
|
| May 12, 2022 |
Alan Denenberg Davis Polk & Wardwell LLP +1 650 752 2004 1600 El Camino Real alan. |
